What question did this study set out to answer?

This research aims to evaluate the effectiveness of MET-TKIs in NSCLC patients with the METex14 skipping mutation, particularly those with poor performance status.

February 2, 20260 citations

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.

View Full Paper

YYYoh YamaguchiMayo Clinic in Arizona TYTatsuya YoshidaNational Cancer Centre Japan RHRyoko Inaba Higashiyama

Key Points

This research aims to evaluate the effectiveness of MET-TKIs in NSCLC patients with the METex14 skipping mutation, particularly those with poor performance status.
Analyzed clinical activity of MET-TKIs in patients with METex14 mutation.
Focused on individuals categorized with poor performance status.
Assessed treatment outcomes in these patients.
Observed limited efficacy of MET-TKIs in patients with poor performance status.
Noted that effectiveness varies based on performance status.
Indicated potential for further study to improve treatment approaches.

Abstract

MET-TKIs are effective for NSCLC with the METex14 skipping mutation; however, their efficacy for patients with a poor PS is limited.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider